The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents

Title: The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents

Volume: 18 Issue: 33

Author(s): D. Secci, A. Bolasco, P. Chimenti and S. Carradori

Affiliation:

Keywords: Alzheimer's disease, anticonvulsant agents, antidepressant agents, isocarboxazid, monoamine oxidase, Parkinson's disease, Porsolt's Test, pyrazole, pyrazolidine, pyrazoline, N-thiocarbamoyl

Abstract: Monoamine oxidase plays a significant role in the control of intracellular concentration of monoaminergic neurotransmitters or neuromodulators and dietary amines. The rapid degradation of these molecules ensures the proper functioning of synaptic neurotransmission and is critically important for the regulation of emotional and other brain functions. The development of human MAO inhibitors led to important breakthroughs in the therapy of several neuropsychiatric disorders. Different families of heterocycles containing 2 or 4 nitrogen atoms have been used as scaffolds for synthesizing selective monoamine oxidase inhibitors, but the early period of the MAO-inhibitors started with hydrazine derivatives. Pyrazole, pyrazoline, and pyrazolidine derivatives can be considered as a cyclic hydrazine moiety. This scaffold also displayed promising antidepressant and anticonvulsant properties as demonstrated by different and established animal models. Diversely substituted pyrazoles, embedded with a variety of functional groups, are important biological agents and a significant amount of research activity has been directed towards this chemical class.

Cite this article as:

Secci D., Bolasco A., Chimenti P. and Carradori S., The State of the Art of Pyrazole Derivatives as Monoamine Oxidase Inhibitors and Antidepressant/Anticonvulsant Agents, Current Medicinal Chemistry 2011; 18 (33) . https://dx.doi.org/10.2174/092986711797636090